Homepage

scientist working
Bakar Labs

Latest News & Upcoming Events

aikium

Tenant Spotlight on Aikium: A Trillion Shots at Targeting Tangled Proteins

Aikium has essentially invented a new protein family. Called “SeqR” proteins, they are sequence specific binders that can be applied to different therapeutic needs such as cancer, neuro-inflammation, and some autoimmune disorders. Aikium is going after chemokine receptors, a subset of G-protein coupled receptors, a large class of molecules that have long proven difficult to target. By virtue of being on immune cells, they are front and center in cancer and immune-mediated diseases. Read post
RVB cells delivering protein therapy continuously on skin

NIH Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome

ResVita Bio is pioneering continuous protein therapy, delivered through a genetically engineered probiotic platform that temporarily colonizes the skin and continuously releases therapeutic proteins, such as LEKTI, to inhibit protease activity. This continuous delivery method ensures high levels of the therapeutic agent at the site of damage, restoring the integrity of the skin barrier. This represents a significant shift from traditional therapies, which may not provide sustained treatment at the site of the disease. Read post
David Hochschild of the California Energy Commission

Launch of Bakar ClimatEnginuity Hub Unites UC Berkeley Climate Tech Community

“Berkeley’s different from Las Vegas: what starts here does not end here,” said Dan Kammen, a UC Berkeley professor of energy and founding director of the Renewable and Appropriate Energy Laboratory, in his keynote address at the symposium to launch the Bakar ClimatEnginuity Hub (BCH), Berkeley’s innovation center and incubator for climate technology. BCH will accelerate the commercialization of new technologies, sending them forth to be adopted by humanity across the world as we adapt to and combat climate change. Read post
Illustration of genetic sequence of zinc finger domains

ARIZ Precision Medicine Announces Grant of Key US Patent Covering Lead Cancer Drug

ARIZ has a proprietary ligand targeted nanoparticle drug delivery system designed to destroy cancer cells, without harming normal cells. ARIZ’s target a family of genes known as the PRDMs (Positive Regulatory Domain-containing Methyltransferases) that are genetic drivers that control cell growth, proliferation, survival and mobility. Studies show that alterations in the expression and activity of the PRDMs are among the first drivers in normal cells that lead to cancer cell formation. The PRDMs have been implicated in solid tumors such as breast, colon, gastric, liver, lung, melanoma, and prostate cancers, as well as in blood cancers such as leukemia, lymphoma and myeloma. Read post
The Bakar ClimatEnginuity Hub, expected to open during the 2027-2028 academic year, will provide a home for entrepreneurs in the burgeoning field of climate technology. The donor-funded facility will be located on the west side of campus at the site currently occupied by University Hall. Rendering by Gensler

Bakar Climate Tech Incubator Recruiting Director of BD & Partnerships

The Director of Business Development and Partnerships of BCH will be responsible for developing highly innovative new programs and partnerships with local, national and international public and private entities to create and support a vibrant ecosystem that accelerates startup companies focused on the translation of scientific discoveries into solutions in the energy and climate tech marketplace. Read post
Bakar Labs in numbers
Powered by QB3

Built for startups. For more than 20 years, QB3 has been the University of California’s center for innovation and entrepreneurship in life science. Through pitch summits, seminars, symposia, podcasts, office hours, internships, and workshops QB3 educates, connects, and elevates the entrepreneurial ecosystem.

Learn about QB3
The members of Allopartis in the QB3 Garage@UCSF incubator